BAYN.DE - Bayer Aktiengesellschaft

XETRA - XETRA Delayed Price. Currency in EUR
62.59
-0.92 (-1.45%)
At close: 5:35PM CET
Stock chart is not supported by your current browser
Previous Close63.51
Open63.61
Bid0.00 x 28400
Ask0.00 x 2100
Day's Range61.66 - 63.87
52 Week Range61.66 - 108.55
Volume5,436,888
Avg. Volume3,904,761
Market Cap58.089B
Beta (3Y Monthly)0.96
PE Ratio (TTM)8.18
EPS (TTM)7.65
Earnings DateFeb 20, 2018 - Feb 26, 2018
Forward Dividend & Yield2.76 (3.88%)
Ex-Dividend Date2018-05-28
1y Target Est120.99
  • Bayer profit flat as weak animal health offsets strong Xarelto
    Reuters Videos4 days ago

    Bayer profit flat as weak animal health offsets strong Xarelto

    Bayer's adjusted core earnings were flat for the quarter, as better prescription numbers for cardiovascular drug Xarelto were tempered by a weaker animal health business and a strong euro weighing on the value of overseas sales. Sonia Legg reports.

  • We Are Optimistic for the Business Overall, Says Bayer CEO
    Bloomberg4 days ago

    We Are Optimistic for the Business Overall, Says Bayer CEO

    Nov.13 -- Werner Baumann, chief executive officer of Bayer AG, discusses the Monsanto acquisition, the value of the stock, shareholder confidence in the company and the possible sale of the animal health and consumer health divisions. He speaks exclusively on "Bloomberg Markets: European Open."

  • Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings
    Zacksyesterday

    Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings

    FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.

  • Reutersyesterday

    California judge orders next Monsanto weed-killer cancer trial for March

    The order by Superior Court Judge Ioana Petrou in Oakland, California, comes on the heels of a $289 million verdict in the first glyphosate trial in San Francisco, in which a jury found Monsanto liable for causing a school groundskeeper's cancer.

  • Reuters2 days ago

    California judge orders next Monsanto weed-killer cancer trial for March

    The order by Superior Court Judge Ioana Petrou in Oakland, California, comes on the heels of a $289 million verdict in the first glyphosate trial in San Francisco, in which a jury found Monsanto liable for causing a school groundskeeper's cancer.

  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of BAYN.DE earnings conference call or presentation 13-Nov-18 1:00pm GMT

    Q3 2018 Bayer AG Earnings Call

  • The Wall Street Journal4 days ago

    [$$] Bayer Hit by More Lawsuits Over Safety of Roundup Weedkiller

    BERLIN—Bayer AG disclosed another jump in the number of lawsuits alleging the German company’s recently acquired weedkillers cause cancer, elevating an issue that has wiped billions off Bayer’s market valuation. Lawsuits from 9,300 plaintiffs were pending at the end of October compared with 8,700 at the end of August, Bayer said Tuesday. Plaintiffs claim that Roundup weedkillers, which Bayer acquired in its takeover of Monsanto Co., made them ill and that Monsanto knew or should have known of the risks but failed to warn adequately.

  • Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates
    Zacks4 days ago

    Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates

    Bayer (BAYRY) surpasses earnings and sales estimates in the third quarter of 2018 and reiterates outlook for 2018.

  • Bayer Vows to Back Roundup as Investors Fret About Crop Unit
    Bloomberg4 days ago

    Bayer Vows to Back Roundup as Investors Fret About Crop Unit

    Bayer earlier reported adjusted earnings that beat analysts’ estimates but also disclosed a rising number of Roundup lawsuits. Bayer repeated that profit and sales will grow this year, even as its consumer health and animal businesses struggle.

  • The Wall Street Journal4 days ago

    [$$] European Equities Market Talk Roundup

    0944 GMT - Henkel’s topline looks “gloomy” ahead of the company’s third-quarter update but there’s hope its margin growth will improve, say analysts at Bernstein. Organic growth should slow to 2.9% due to tougher comparatives and additional headwinds in its adhesives unit, Bernstein says. “Specifically, we expect adhesives to slow to 4.3%, while laundry should decelerate slightly and beauty should be broadly stable,” Bernstein says.

  • Reuters4 days ago

    European shares rebound as trade hopes chase tech scares

    European shares rose in early deals on Tuesday as hopes for a de-escalation of the Sino-U.S. tariff war chased the previous session's fears about a possible downfall of technology stocks after suppliers of Apple cut their forecasts. The pan-European STOXX 600 gained 0.8 percent by 0834 GMT despite Wall Street's main indexes sustaining heavy losses on Monday. Europe's tech sector rose 1.2 percent after falling 3.7 percent during the previous session in New York when the Nasdaq had fallen more than two percent.

  • Financial Times4 days ago

    [$$] Bayer reports flat earnings, plans to challenge weedkiller ruling

    In what are the first set of quarterly results to fully consolidate the effect of its 2016 purchase of US seed business Monsanto, the company said sales in the third quarter rose 1.9 per cent to €9.9bn, while core earning before interest, tax, depreciation and amortisation were flat over the year at €2.2bn. “Crop science posted a substantial rise in earnings due to the acquisition, while pharmaceuticals saw encouraging development. The addition of Monsanto accounted for €2.2bn out of €3.7bn of sales in the group’s crop science division, and made a significant contribution to the division’s ebitda.

  • The Wall Street Journal4 days ago

    [$$] Bayer Earnings Drop as Weedkiller Lawsuits Increase

    The German chemical and pharmaceutical group said 9,300 plaintiffs have now brought lawsuits over glyphosate-based weedkillers made by the recently acquired Monsanto group, compared with 8,700 at the end of August.

  • Ken Fisher Sells Berkshire, Bayer
    GuruFocus.com5 days ago

    Ken Fisher Sells Berkshire, Bayer

    The founder, executive chairman and co-chief investment officer of Fisher Investments, Ken Fisher (Trades, Portfolio), sold shares in the following stocks during the third quarter. Warning! GuruFocus has detected 4 Warning Sign with BRK.B. Click here to check it out. The guru almost closed his Berkshire Hathaway Inc. Class B (BRK.B) position after a reduction of 91.08%.

  • What's in the Cards for Bayer (BAYRY) This Earnings Season?
    Zacks5 days ago

    What's in the Cards for Bayer (BAYRY) This Earnings Season?

    Bayer (BAYRY) is scheduled to report third-quarter earnings on Nov 13. Acquisition of Mosanto is expected to boost sales of Crop Science segment significantly.

  • Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line
    Zacks11 days ago

    Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line

    Regeneron (REGN) Q3 results beat on earnings, while sales meet expectations. However, the company's dependence on Eylea to boost revenues is a concern.

  • Reuters11 days ago

    Germany to use all legal options to end use of glyphosate - minister

    German Environment Minister Svenja Schulze said on Tuesday that her ministry would use all legal options available to end the use of glyphosate-based weed-killers and added that Germany wanted to change the approval process for all pesticides. "If other perhaps even more damaging pesticides are used instead of glyphosate, the environment won't be any better off so we will demand new nature conservation requirements for the approval process of every pesticide that harms biodiversity," Schulze said.

  • Bayer CEO says would consider glyphosate settlement depending on costs
    Reuters15 days ago

    Bayer CEO says would consider glyphosate settlement depending on costs

    Bayer AG's chief executive said this week the company might consider settling lawsuits over Monsanto's glyphosate-containing weed-killers depending on how high court costs rise, but stressed it remained focused on defending the combined company against claims they cause cancer. Bayer acquired Monsanto this year for $63 billion. "If we can settle nuisances at some point where the defense costs in preparing cases are higher than potential settlement amounts, we will of course consider it from an economic standpoint," CEO Werner Baumann told reporters when asked whether there was any scenario in which Bayer would consider settling.

  • Reuters15 days ago

    Bayer CEO says would consider glyphosate settlement depending on costs

    Bayer AG's (BAYGn.DE) chief executive said this week the company might consider settling lawsuits over Monsanto's glyphosate-containing weed-killers depending on how high court costs rise, but stressed it remained focussed on defending the combined company against claims they cause cancer. Bayer acquired Monsanto this year for $63 billion (£48.4 billion). "If we can settle nuisances at some point where the defence costs in preparing cases are higher than potential settlement amounts, we will of course consider it from an economic standpoint," CEO Werner Baumann told reporters when asked whether there was any scenario in which Bayer would consider settling.

  • Reuters15 days ago

    Bayer CEO backs group's diversified structure

    Bayer's (BAYGn.DE) chief executive reaffirmed his support for a corporate structure made up of healthcare, crop science and animal health businesses, after analysts called for a breakup to shore up its flagging share price. Shares in drugmaker Bayer, which bought Monsanto for $63 billion (£48.4 billion) , have lost more than 25 percent since a U.S. jury in August found its glyphosate-based weedkillers responsible for a man's terminal cancer, with more than 8,700 plaintiffs also seeking damages. "We have announced our strategy in September 2014, which has not changed to date," Chief Executive Werner Baumann told journalists in St. Louis at the former Monsanto headquarters where Bayer's seed business is now based.

  • Reuters17 days ago

    PRESS DIGEST- Wall Street Journal - Nov 1

    The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - BHP Billiton Ltd said it would hand $10.4 billion to shareholders ...

  • The Wall Street Journal17 days ago

    [$$] EPA Allows Farmers to Keep Using Bayer’s Controversial Weedkiller

    The Environmental Protection Agency will continue to allow farmers to spray crops with a controversial weedkiller, while tightening restrictions, the agency said. The EPA extended by two years its approval of XtendiMax, a version of the herbicide dicamba made by Bayer AG, which some farmers and researchers have blamed for damaging millions of acres of crops over the past two years. The decision is a win for Bayer, which also markets soybean and cotton seeds genetically engineered to survive the chemical.

  • Reuters17 days ago

    EPA adds restrictions to use of Bayer, BASF weed killer linked to crop damage

    The U.S. Environmental Protection Agency said on Wednesday it would allow farmers to spray a controversial weed killer made by Bayer AG's Monsanto Co and BASF SE for two more years, with additional restrictions on use. The agency said the herbicide, called dicamba, is an important tool for controlling weeds in crop fields.

  • Groundskeeper accepts reduced $78 million Monsanto verdict
    Associated Press17 days ago

    Groundskeeper accepts reduced $78 million Monsanto verdict

    SAN FRANCISCO (AP) — A Northern California groundskeeper said Wednesday that he will accept a judge's reduced verdict of $78 million against Monsanto after a jury found the company's weed killer caused his cancer.